Main Uses of MACI

MACI (matrix-applied characterized autologous cultured chondrocytes) is a cellular therapy used for the repair of symptomatic, full-thickness cartilage defects in the knee. It is specifically designed for patients who have experienced a loss of articular cartilage due to acute or repetitive trauma.

The procedure is indicated for the treatment of single or multiple defects, which may be located on the:

• Femoral condyles: The rounded projections at the end of the thigh bone.
• Patella: The kneecap.

MACI is intended for use in skeletally mature adults. It is typically considered when the cartilage damage is significant enough to cause pain or functional limitations but has not yet progressed to generalized osteoarthritis.

Potential Benefits

The primary goal of MACI is to restore the cartilage surface of the knee joint using the patient's own cells. By regenerating hyaline-like cartilage, the therapy aims to address the underlying structural damage rather than just managing symptoms.

Restoration of Joint Surface

Unlike some marrow-stimulating techniques that may result in the formation of fibrocartilage—which is less durable—MACI aims to produce a repair tissue that mimics the structural and mechanical properties of natural hyaline cartilage.

Improvement in Symptoms and Function

Patients undergoing this treatment may experience several clinical benefits over the long term, including:

• Pain Reduction: Relief from the chronic discomfort associated with cartilage lesions.
• Increased Mobility: Improved ability to perform daily activities and movements that were previously restricted by the injury.
• Enhanced Quality of Life: A return to more active lifestyles through improved joint stability and function.

Targeted Repair

Because MACI uses a porcine-derived collagen membrane to deliver the cultured cells, it allows for precise placement within the defect. This ensures that the new cell growth is concentrated exactly where the cartilage loss has occurred, facilitating a more integrated repair with the surrounding healthy tissue.

Eligibility for MACI: Official Regulatory Profile

MACI (autologous cultured chondrocytes) is indicated for repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee.

---

Absolute Contraindications

MACI is contraindicated and must not be used in patients with:

• A known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin.
• Severe osteoarthritis of the knee, inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders.
• The inability to cooperate with a physician-prescribed post-surgical rehabilitation program.

---

Age and Specific Population Limitations

Regulatory documents establish boundaries for use based on age and physiological status:

• Pediatric Use: Use in patients younger than 18 years of age has not been established.
• Older Adults: Safety and effectiveness have not been established in patients over the age of 55 or over 65 years.
• Pregnancy: The implant is not recommended during pregnancy.
• Lactation: Safety for breastfeeding infants has not been determined.

Additionally, conditions such as local infection, ligament instability, or malalignment must be assessed and treated prior to or concurrent with implantation.

MACI Interactions with other medicines and products

Official documentation on the interaction profile of MACI (Matrix-Applied Characterized Autologous Cultured Chondrocytes) is primarily defined by material-based restrictions, consistent with its classification as an Advanced Therapy Medicinal Product (ATMP).

As a surgically implanted, localized cellular product, MACI does not undergo systemic metabolism and is not subject to formal drug interaction studies common for orally administered small-molecule drugs. Consequently, regulatory sources document the absence of systemic pharmacokinetic (PK) and pharmacodynamic (PD) interactions.

Interaction-Related Restrictions

Classification	Restricted Substances/Products	Regulatory Basis
Contraindicated Combinations	Substances containing Gentamicin or other Aminoglycosides	Risk of hypersensitivity reaction to trace manufacturing residues.
Contraindicated Combinations	Products of Porcine or Bovine Origin	Risk of hypersensitivity reaction to the porcine collagen membrane scaffold.

No mandatory separation or spacing requirements are documented for co-administering other medicines. The official interaction structure focuses on prohibiting use in individuals with known hypersensitivity to the materials or trace components of the final product.

The MACI (Matrix-Applied Chondrocytes for Induction) procedure functions through a regenerative mechanism centered on autologous cellular activity, distinct from pharmacological pathways. The process begins with the localized implantation of autologous chondrocytes (patient-derived cartilage cells) seeded onto a collagen membrane scaffold. The delivery is targeted precisely to the articular cartilage defect, supplying the necessary cell type for chondrogenesis.

Following implantation, the chondrocytes engage a regenerative cascade. The cells are activated to proliferate within the defect site and transition to synthesizing a new extracellular matrix (ECM). This biosynthetic process involves the production of Type II collagen and proteoglycans, which are the structural components of the native cartilage matrix. The collagen scaffold provides a temporary template, facilitating the mechanical retention and structural organization of the new tissue. This mechanism results in the progressive formation of a hyaline-like cartilage matrix that integrates with the existing joint surface.

How to Use MACI: Official Administration Guidelines

MACI (Matrix-Applied Characterized Autologous Cultured Chondrocytes) is administered via a highly controlled surgical procedure, not as a conventional drug regimen. The principles for its use are defined to ensure precise and patient-specific application.

---

Administration Scope

Instruction	Official Guideline
Route of Administration	Surgical implantation directly into the prepared cartilage defect, typically via arthrotomy (open) or arthroscopy.
Dosing Schedule	The amount of implant is customized to the defect's size (cm^2); the membrane contains a cell density between 500,000 to 1,000,000 viable cells per cm^2.
Frequency and Timing	The implant is intended for a single application per treated cartilage defect.
Preparation Requirements	The defect area must be prepared down to the subchondral plate; penetration of the subchondral bone must be avoided.

---

Procedural and Population Requirements

Instruction	Official Guideline
Age-Group Rules	Use has not been assessed in patients under 18 or over 55 years of age. The procedure is not recommended during pregnancy.
Special Conditions	Requires strict autologous use, meaning the implant must only be administered following verification of patient identifiers to match the sample source.
Post-Operative Management	The implantation must be immediately followed by a physician-prescribed, structured rehabilitation program.

---

Connection to the Overall Use Protocol

The official administration guidelines establish MACI use as a multi-stage, single surgical application dependent on the precise anatomical fit of the implant, which is trimmed to the injury's exact dimensions. This process is governed by mandatory autologous identity verification and is formally concluded only once the required post-operative rehabilitation phase is underway, as outlined in the official product labeling.

Research Evidence: Overview of Studies for MACI

This section provides an overview of the research studies and clinical trials that was studied for MACI, based on information from official regulators and peer-reviewed scientific literature. This is a descriptive summary of the research landscape and is not clinical advice or a guarantee of personal outcome.

---

Evidence for Use in Symptomatic Cartilage Defects of the Knee

The clinical evaluation for MACI was studied for skeletally mature adults presenting with symptomatic, full-thickness articular cartilage defects in the knee.

The core evidence for this use comes primarily from Randomized Controlled Trials (RCTs), a type of research design known for its comparative structure, alongside long-term observation studies. These trials were applied in studies examining patient-reported experiences, where researchers studied whether changes occurred in patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning over specific time intervals. Research explored the structural characteristics of the new tissue formed at the repair site using imaging techniques.

---

Research Comparing MACI to Standard Surgical Repair

Research also focused on comparing MACI directly against microfracture, an established, non-cellular surgical procedure. The comparative trials evaluated the proportion of patients achieving a predefined successful outcome for knee function and pain. Reports described patterns observed in the studies regarding these measurements. These findings help contextualize how patients reported their experience.

---

Long-Term Studies and Durability of Functional Outcomes

Follow-up studies have explored short-term symptom changes and the stability of the knee over time. Research describes that the available functional data was observed in the studied populations for up to five years. Data on outcomes for periods longer than five years are still emerging, and long-term outcomes are not fully established.

---

Evidence in Restricted and Special Populations

Evidence is limited for individuals who are over the age of 55 or those who are still growing (pediatric patients), and data for certain groups remain insufficient for these populations. Research was studied for defects in the knee joint; comparative evidence is lacking for the use of MACI in joints other than the knee.

Common questions about MACI (FAQ)

Q: How is MACI different from microfracture surgery for cartilage repair?

A: MACI is considered a later-generation cartilage repair technique compared to microfracture. The MACI procedure involves placing a patient's own grown cartilage cells onto a specialized membrane. Clinical studies supported a finding of improved knee function and sustained tissue repair in the MACI group compared to the microfracture group in the studied patient population.

Q: Is MACI an approved treatment for cartilage damage in joints other than the knee?

A: According to official product information, the effectiveness of MACI has not been established for treating cartilage damage in joints other than the knee. The treatment is currently indicated only for symptomatic, full-thickness cartilage defects within the knee joint.

Q: Does MACI require a formal physical therapy regimen, and if so, for approximately how long?

A: Yes, regulatory documents state that the MACI procedure must be immediately followed by a physician-prescribed, structured rehabilitation program. While the specific duration is determined by the physician, clinical guidelines often describe a program lasting 9 to 12 months to progressively support patient function. The timeline for returning to activities is individually managed.

Q: Are there any restrictions on the use of blood thinners around the time of the MACI procedure?

A: Official prescribing information lists a known restriction: MACI is contraindicated (must not be used) in patients with uncorrected congenital blood coagulation disorders. Consultation with your physician is necessary regarding the temporary management of any other prescribed blood thinners around the time of the surgical procedure.

Q: Are there any reports of immune system rejection or reactions to the MACI implant?

A: Official information notes that the autologous cell source (the patient's own cells) reduces the risk of immunological complications. However, official safety information states the product is contraindicated for people with a known history of hypersensitivity to the implant's components, which include trace amounts of gentamicin and materials of porcine or bovine origin.

Q: What is the reported success rate of MACI as detailed in regulatory submission documents?

A: In the pivotal clinical trial that supported regulatory approval, 87.5% of patients treated with MACI were classified as responders after two years. A responder was defined as a patient achieving a predefined threshold of improvement in specific pain and functional assessment scores.

Q: Why is the MACI procedure typically performed in two separate surgical stages?

A: The MACI procedure requires two distinct surgical stages because the cartilage cells harvested in the initial biopsy must be sent to a specialized laboratory. This is necessary for the cells to be cultured and expanded over several weeks to achieve the necessary cell density required to create the final implant.

Q: What is the typical time frame between the initial biopsy and the MACI implant surgery?

A: The time frame between the initial biopsy and the final implantation procedure is determined by the cell culturing process. This laboratory process typically takes approximately 8 to 12 weeks for the cells to be properly expanded and prepared for use.

Q: When can patients generally expect to start putting weight on the treated knee after the MACI procedure?

A: Weight bearing is strictly restricted immediately after surgery, often limited to toe-touch ambulation using crutches. According to rehabilitation guidelines, the goal is generally to achieve full weight bearing on the treated knee by 8 to 12 weeks post-surgery. This timeline is determined by the supervising physician.

Q: Are there specific movements or physical activities that should be avoided immediately after MACI implantation?

A: Yes, post-operative rehabilitation protocols limit specific movements to support the healing of the graft site. Activities to be avoided include excessive load bearing, using the knee without crutches or a brace, creating shear forces within the joint, and flexing the knee beyond the angles specified by the physician.

Q: Can MACI be used if a patient has a history of multiple previous knee surgeries?

A: The official product label does not strictly prohibit the use of MACI based on a patient's history of prior knee surgeries. However, official clinical research has suggested that the number of previous knee surgeries, such as three or more, may be a factor that influences the long-term clinical outcome.

Q: What does official research say about the long-term need for repeat procedures after MACI?

A: Long-term follow-up studies spanning more than 10 years reported a low rate of requiring repeat procedures. Research indicates that the survival rate against revision surgery for any reason was estimated to be approximately 97% at 10 years in the studied patient population.

Q: What are the eligibility rules regarding the patient's weight or BMI?

A: The official product label does not list a specific restriction based on the patient's Body Mass Index (BMI). However, clinical research data suggests that BMI may be a factor influencing long-term outcomes, with analysis identifying an optimal range (e.g., 20 to 29) for the most favorable results.

Q: What are the typical restrictions on driving after the MACI surgery?

A: Official regulatory sources and prescribing information do not specify a fixed date for returning to driving. Restrictions are determined individually by the physician based on the patient's functional recovery, the ability to safely operate the vehicle, and the required use of crutches or a brace.

The official requirements for storing and disposing of MACI (autologous cultured chondrocytes on porcine collagen membrane) are regulated to preserve the implant’s living cells prior to surgery.

Mandatory Storage and Handling

Condition	Requirement
Temperature	Store at room temperature (15 C to 25 C) after the shipping box is opened.
Protection	Do not freeze and do not refrigerate the product.
Stability Limit	Use within 6 hours of opening the shipping box, if not already expired.
Packaging	Keep the implant in its original packaging and ensure the bottle remains upright until the time of implantation.

Disposal Instructions

Any unused MACI product (implant and transport medium) must be disposed of immediately according to local site procedures for biological waste. Components of the surgical kit used on a patient with suspected Creutzfeldt-Jakob Disease (CJD) must be destroyed.